Genmab A/S (NASDAQ:GMAB) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Genmab A/S (NASDAQ:GMAB) issued its earnings results on Wednesday. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03), Zacks reports. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The business had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the prior year, the business posted $0.47 EPS. Genmab A/S updated its FY 2024 guidance to EPS.

Genmab A/S Trading Up 3.5 %

NASDAQ GMAB traded up $0.78 during trading hours on Thursday, reaching $23.11. 1,266,500 shares of the company traded hands, compared to its average volume of 670,717. The stock has a market capitalization of $15.29 billion, a PE ratio of 19.04, a PEG ratio of 0.68 and a beta of 0.99. Genmab A/S has a 12 month low of $21.90 and a 12 month high of $32.89. The company has a 50 day moving average of $24.57 and a two-hundred day moving average of $26.47.

Wall Street Analyst Weigh In

A number of research analysts have commented on GMAB shares. Truist Financial reduced their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.